Call for South Asian bone marrow donors to save four-year-old

Esha Nadeswaran from London has leukaemia and needs a stem cell donor to save her life.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news

Related Links:

Clin Lymphoma Myeloma Leuk. 2021 Aug 2:S2152-2650(21)00315-3. doi: 10.1016/j.clml.2021.07.031. Online ahead of print.ABSTRACTMyelodysplastic syndromes (MDS) are a group of heterogeneous clonal hematopoietic stem cell disorders. The 2020 Surveillance, Epidemiology, and End Results data demonstrates the incidence rate of MDS increases with age especially in those greater than 70 years of age. Risk stratification that impact prognosis, survival, and rate of acute myeloid leukemia (AML) transformation in MDS is largely dependent on revised International Prognostic Scoring System along with molecular genetic testing as a supple...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
We describe a rare case of a 70-year-old man presenting with MS of the urinary bladder complicating known secondary AML (RUNX1 and IDH2 mutated). Prior to development of bladder MS, the patient had received decitabine, enasidenib, and venetoclax. Following diagnosis, he was treated with cytarabine and venetoclax. To our knowledge, this is the first case of bladder MS treated with a BCL-2 inhibitor.Case Rep Oncol 2021;14:1366 –1372
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Contributors : He-zhou Guo ; Jiang ZhuSeries Type : Expression profiling by arrayOrganism : Mus musculusRecent studies suggest that bone marrow stromal cells are critical for forming a niche that maintains hematopoietic stem cells ’ quiescence and adapt blood production to the organism’s needs. Alterations in the bone marrow niche are commonly observed in blood malignancies and directly contribute to the aberrant function of disease-initiating leukemic stem cells.We used microarrays to detail the global programme of stromal cells' gene expression during leukemic progression.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
In conclusion, a substantial proportion of patients with AML will develop RR AML, which is associated with significant humanistic and economic burden. Existing treatments offer limited efficacy, highlighting the need for more effective non-intensive treatment options.PMID:34540343 | PMC:PMC8446831
Source: Cell Research - Category: Cytology Authors: Source Type: research
ConclusionThis combination treatment showed high clinical activity. However, biological activity needs to be further characterized in prospective clinical trials.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
We describe a 67-year-old patient with long-standing untreated B1 thymoma that presented with constitutional symptoms and a painless soft tissue mass on the right chest wall. Pathological analysis of the biopsy from the mass demonstrated T-lymphoblastic leukemia/lymphoma. The patient went through a complicated course, was refractory to several lines of therapy, and eventually underwent allogeneic hematopoietic stem cell transplantation in complete remission from a matched related donor. The association between thymoma and malignant neoplasms has been described in the literature, most notably with colorectal adenocarcinoma ...
Source: Acta Haematologica - Category: Hematology Authors: Source Type: research
Allogeneic hematopoietic cell transplant (allo-HCT) has been shown to provide a significant overall survival (OS) benefit in patients with acute myeloid leukemia (AML) and intermediate or poor risk cytogenetics compared to patients that did not undergo allo-HCT in multiple studies.1-4 Similar OS benefits with allo-HCT have been documented in patients with higher-risk myelodysplastic syndromes (MDS).5, 6 The advent of reduced intensity conditioning (RIC) allo-HCT has expanded transplant eligibility for older patients and those with significant comorbidities with favorable outcomes compared to non-transplant strategies.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
AbstractAcute myeloid leukemia (AML) relapse after allogeneic stem cell transplant (alloSCT) remains a major therapeutic challenge. While patients with longer remission after initial alloSCT are recommended to receive cell therapy (CT) such as 2ndalloSCT or donor lymphocyte infusion (DLI), survival for patients who relapse within 6  months of alloSCT has been dismal. We evaluated the outcomes of AML relapse after alloSCT to assess the impact of different treatments on long-term survival. One hundred and seventy-two patients with AML underwent alloSCT at the Penn State Cancer Institute from January 2014 to August 2019....
Source: Annals of Hematology - Category: Hematology Source Type: research
We describe a 67-year-old patient with long-standing untreated B1 thymoma that presented with constitutional symptoms and a painless soft tissue mass on the right chest wall. Pathological analysis of the biopsy from the mass demonstrated T-lymphoblastic leukemia/lymphoma. The patient went through a complicated course, was refractory to several lines of therapy, and eventually underwent allogeneic hematopoietic stem cell transplantation in complete remission from a matched related donor. The association between thymoma and malignant neoplasms has been described in the literature, most notably with colorectal adenocarcinoma ...
Source: Acta Haematologica - Category: Hematology Source Type: research
Haematologica. 2021 Sep 16. doi: 10.3324/haematol.2020.266155. Online ahead of print.ABSTRACTNot available.PMID:34525792 | DOI:10.3324/haematol.2020.266155
Source: Haematologica - Category: Hematology Authors: Source Type: research
More News: Health | Leukemia | Stem Cell Therapy | Stem Cells